871014-16-3

Basic information

• Product Name: trans-3-[(tert-butoxycarbonyl)amino]cyclobutyl 4-nitrobenzoate
• Synonyms: trans-3-[(tert-butoxycarbonyl)amino]cyclobutyl 4-nitrobenzoate
• CAS NO: 871014-16-3
• Molecular Weight: 336.345
• Mol File: 871014-16-3.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: trans-3-[(tert-butoxycarbonyl)amino]cyclobutyl 4-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: trans-3-[(tert-butoxycarbonyl)amino]cyclobutyl 4-nitrobenzoate(871014-16-3)
• EPA Substance Registry System: trans-3-[(tert-butoxycarbonyl)amino]cyclobutyl 4-nitrobenzoate(871014-16-3)

Safety Data

• Hazardous Substances Data: 871014-16-3(Hazardous Substances Data)

Upstream product

• 154748-49-9 3-(tert-butyloxycarbonylamino)cyclobutan-1-one 
• 389890-43-1 tert-butyl (1,3-cis)-N-(3-hydroxycyclobutyl)carbamate 
• 62-23-7 4-nitro-benzoic acid 

Downstream Products

• 389890-42-0 tert-butyl N-[(1r,3r)-3-hydroxycyclobutyl]carbamate 
• 154748-63-7 tert-butyl ((1s,3s)-3-hydroxycyclobutyl)carbamate 

Relevant articles and documents

Novel CDK inhibitory compounds, preparation method thereof, pharmaceutical composition for use in preventing or treating CDK relating diseases containing the same as an active ingredient

The present invention relates to a novel CDK inhibitory compound, a method for manufacturing the same, and a pharmaceutical composition for preventing or treating a CDK-related disease containing the compound as an active ingredient. The novel CDK inhibit

DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS

The present disclosure is based, in part, on the discovery that disclosed compounds can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.

COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY

The present disclosure features compounds such as those having the Formulae (Ila), (lIb), (lIc), (Ild), (IlIa), and (Illb), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (Ila), (lIb), (lIc), (lId), (IlIa), or (Illb).